Up to 40% of patients with classic hairy cell leukemia relapse within 10 to 15 years. An NIH researcher explains how adding Rituxan up front may help.
News|Articles|September 17, 2026
Dr. Dina Khalaf Breaks Down 3 Trials Advancing AML, MDS Care
Author(s)Spencer Feldman
Fact checked by: CURE staff
Dr. Dina Khalaf explains the ASCERTAIN-V, MyeloMATCH MM1MDS-A01 and HOVON 181 trials and what patients with AML or MDS should ask before enrolling.
Advertisement
Advertisement
In this Q&A, Dr. Dina Khalaf, a clinical associate professor in the University of Florida Division of Hematology and Oncology, discusses three clinical trials advancing treatment for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS): ASCERTAIN-V, MyeloMATCH MM1MDS-A01 and HOVON 181 AML/AMLSG 37-25.
Related to this article
Dr. Rebecca Dent explains how Datroway kept brain metastases in check longer than chemotherapy in triple-negative breast cancer, and what patients should know.
Dr. Matteo Lambertini explains how Lynkuet reduced hot flashes in people on endocrine therapy for breast cancer, no matter when their treatment began.
Gita Kwatra, PharmD, MBA, co-founder and CEO of the Glioblastoma Foundation, discusses why every patient with glioblastoma should have their tumor profiled, and what patients can ask their care team.
Dr. Sara Hurvitz explains why giving Enhertu before surgery didn't change care for HER2-low, HR-positive early breast cancer, and what patients should know.
After nearly a year of chemotherapy, a patient with stage 4 pancreatic cancer describes daily life and side effects on Rasonque (daraxonrasib).
Ohio State hematologist Dr. Kerry Rogers says chemotherapy and newer targeted drugs both work well, and the right choice depends on the patient.
Given an 18-month prognosis for peritoneal mesothelioma in 2007, a mother shares the joy of tapping her son out at his Air Force basic training graduation.
Advertisement
Advertisement